2. Espinosa-Sanchez JM, Lopez-Escamez JA. Meniere’s disease. Handb Clin Neurol. 2016;137:257-77.
3. Stahle J, Friberg U, Svedberg A. Long-term progression of Meniere’s disease. Acta Otolaryngol Suppl. 1991;485:78-83.
4. Lopez-Escamez JA, Carey J, Chung WH, Goebel JA, Magnusson M, Mandala M, et al. Diagnostic criteria for Meniere’s disease. J Vestib Res. 2015 Mar;25(1):1-7.
6. Frejo L, Martin-Sanz E, Teggi R, Trinidad G, Soto-Varela A, SantosPerez S, et al. Extended phenotype and clinical subgroups in unilateral Meniere disease: a cross-sectional study with cluster analysis. Clin Otolaryngol. 2017 Dec;42(6):1172-80.
7. Requena T, Espinosa-Sanchez JM, Cabrera S, Trinidad G, Soto-Varela A, Santos-Perez S, et al. Familial clustering and genetic heterogeneity in Meniere’s disease. Clin Genet. 2014 Mar;85(3):245-52.
8. Lee JM, Kim MJ, Jung J, Kim HJ, Seo YJ, Kim SH. Genetic aspects and clinical characteristics of familial Meniere’s disease in a South Korean population. Laryngoscope. 2015 Sep;125(9):2175-80.
9. Roman-Naranjo P, Gallego-Martinez A, Lopez Escamez JA. Genetics of vestibular syndromes. Curr Opin Neurol. 2018 Feb;31(1):105-10.
10. Birgerson L, Gustavson KH, Stahle J. Familial Meniere’s disease: a genetic investigation. Am J Otol. 1987 Jul;8(4):323-6.
11. Klar J, Frykholm C, Friberg U, Dahl N. A Meniere’s disease gene linked to chromosome 12p12.3. Am J Med Genet B Neuropsychiatr Genet. 2006 Jul;141(5):463-7.
12. Morrison AW, Bailey ME, Morrison GA. Familial Meniere’s disease: clinical and genetic aspects. J Laryngol Otol. 2009 Jan;123(1):29-37.
13. Oliveira CA, Ferrari I, Messias CI. Occurrence of familial Meniere’s syndrome and migraine in Brasilia. Ann Otol Rhinol Laryngol. 2002 Mar;111(3 Pt 1):229-36.
14. Arweiler-Harbeck D, Horsthemke B, Jahnke K, Hennies HC. Genetic aspects of familial Meniere’s disease. Otol Neurotol. 2011 Jun;32(4):695-700.
15. Hietikko E, Kotimaki J, Okuloff A, Sorri M, Mannikko M. A replication study on proposed candidate genes in Meniere’s disease, and a review of the current status of genetic studies. Int J Audiol. 2012 Nov;51(11):841-5.
16. Roman-Naranjo P, Gallego-Martinez A, Soto-Varela A, Aran I, Moleon M, Espinosa-Sanchez JM, et al. Burden of rare variants in the OTOG gene in familial Meniere’s disease. Ear Hear. 2020 Nov/Dec;41(6):1598-605.
17. Sajjadi H, Paparella MM. Meniere’s disease. Lancet. 2008 Aug;372(9636):406-14.
18. Paparella MM, Djalilian HR. Etiology, pathophysiology of symptoms, and pathogenesis of Meniere’s disease. Otolaryngol Clin North Am. 2002 Jun;35(3):529-45.
19. Greco A, Gallo A, Fusconi M, Marinelli C, Macri GF, de Vincentiis M. Meniere’s disease might be an autoimmune condition. Autoimmun Rev. 2012 Aug;11(10):731-8.
21. Joannovic D. Zur Wirkung fermentativ gewonner spaltungsprodukte aus Geweben und Bakterien. Wein Klin Wschr. 1920;70:1410-11.
22. Masugi M, Tomizuka Y. Uber die spezifisch zytotoxischen Veranderungen der Niere und sehr Leber durch das spezifische Antiserum (Nephrotoxin und Hepatoxin). Trans Jap Pathol. 1931;21:329-41.
23. Lehnhardt E. Pathogenesis of sudden hearing disorders. Dtsch Gesundheitsw. 1958 Jan;13(4):105-9.
24. Kikuchi M. On the “sympathetic otitis.” Zibi Rinsyo Kyoto. Dtsch Gesundheitsw. 1959;52:600.
25. Beickert P. On the problem of perception deafness and autoallergy. Z Laryngol Rhinol Otol. 1961 Nov;40:837-42.
26. Yoshihiko T, Yukihiro S. Studies on experimental allergic (isoimmune) labyrinthitis in guinea pigs. Acta Otolaryngol. 1964 Jul;58:49-64.
27. McCabe BF. Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol. 1979 Sep-Oct;88(5 Pt 1):585-9.
28. Verdoodt D, Van Camp G, Ponsaerts P, Van Rompaey V. On the pathophysiology of DFNA9: effect of pathogenic variants in the COCH gene on inner ear functioning in human and transgenic mice. Hear Res. 2021 Mar;401:108162.
29. Baruah P. Cochlin in autoimmune inner ear disease: is the search for an inner ear autoantigen over. Auris Nasus Larynx. 2014 Dec;41(6):499-501.
30. Danial-Farran N, Chervinsky E, Nadar-Ponniah PT, Cohen Barak E, Taiber S, Khayat M, et al. Homozygote loss-of-function variants in the human COCH gene underlie hearing loss. Eur J Hum Genet. 2021 Feb;29(2):338-42.
31. Jung J, Yoo JE, Choe YH, Park SC, Lee HJ, Lee HJ, et al. Cleaved cochlin sequesters pseudomonas aeruginosa and activates innate immunity in the inner ear. Cell Host Microbe. 2019 Apr;25(4):513-25.
32. Hughes GB, Kinney SE, Barna BP, Calabrese LH. Autoimmune reactivity in Meniere’s disease: a preliminary report. Laryngoscope. 1983 Apr;93(4):410-7.
33. Tyrrell JS, Whinney DJ, Ukoumunne OC, Fleming LE, Osborne NJ. Prevalence, associated factors, and comorbid conditions for Meniere’s disease. Ear Hear. 2014 Jul-Aug;35(4):e162-9.
34. Hietikko E, Kotimaki J, Sorri M, Mannikko M. High incidence of Meniere-like symptoms in relatives of Meniere patients in the areas of Oulu University Hospital and Kainuu Central Hospital in Finland. Eur J Med Genet. 2013 Jun;56(6):279-85.
36. Bovo R, Ciorba A, Martini A. Vertigo and autoimmunity. Eur Arch Otorhinolaryngol. 2010 Jan;267(1):13-9.
37. Chiarella G, Di Domenico M, Petrolo C, Saccomanno M, Rothenberger R, Giordano A, et al. A proteomics-driven assay defines specific plasma protein signatures in different stages of Meniere’s disease. J Cell Biochem. 2014 Jun;115(6):1097-100.
38. Lopez-Escamez JA, Saenz-Lopez P, Gazquez I, Moreno A, Gonzalez-Oller C, Soto-Varela A, et al. Polymorphisms of CD16A and CD32 Fcγ receptors and circulating immune complexes in Meniere’s disease: a case-control study. BMC Med Genet. 2011 Jan;12:2.
39. Gloddek B, Arnold W. Clinical and experimental studies of autoimmune inner ear disease. Acta Otolaryngol Suppl. 2002;(548):10-4.
40. Yoo TJ, Yazawa Y, Tomoda K, Floyd R. Type II collagen-induced autoimmune endolymphatic hydrops in guinea pig. Science. 1983 Oct;222(4619):65-7.
41. Yoo TJ. Etiopathogenesis of Meniere’s disease: a hypothesis. Ann Otol Rhinol Laryngol Suppl. 1984 Sep-Oct;113:6-12.
42. Brookes GB. Circulating immune complexes in Meniere’s disease. Arch Otolaryngol Head Neck Surg. 1986 May;112(5):536-40.
43. Yoo TJ, Shea J Jr, Ge X, Kwon SS, Yazawa Y, Sener O, et al. Presence of autoantibodies in the sera of Meniere’s disease. Ann Otol Rhinol Laryngol. 2001 May;110(5 Pt 1):425-9.
44. Bernstein JM, Shanahan TC, Schaffer FM. Further observations on the role of the MHC genes and certain hearing disorders. Acta Otolaryngol. 1996 Sep;116(5):666-71.
45. Gazquez I, Moreno A, Aran I, Soto-Varela A, Santos S, Perez-Garrigues H, et al. MICA-STR A.4 is associated with slower hearing loss progression in patients with Meniere’s disease. Otol Neurotol. 2012 Feb;33(2):223-9.
46. Requena T, Gazquez I, Moreno A, Batuecas A, Aran I, Soto-Varela A, et al. Allelic variants in TLR10 gene may influence bilateral affectation and clinical course of Meniere’s disease. Immunogenetics. 2013 May;65(5):345-55.
49. Xu WD, Zhao Y, Liu Y. Role of the TWEAK/Fn14 pathway in autoimmune diseases. Immunol Res. 2016 Feb;64(1):44-50.
50. Rask-Andersen H, Danckwardt-Lilliestrom N, Friberg U, House W. Lymphocyte-macrophage activity in the human endolymphatic sac. Acta Otolaryngol Suppl. 1991;485:15-7.
51. Okano T, Nakagawa T, Ito J. Distribution of bone marrow-derived cells in the vestibular end organs and the endolymphatic sac. Acta Otolaryngol Suppl. 2010 Nov;(563):88-94.
52. Moller MN, Kirkeby S, Vikesa J, Nielsen FC, Caye-Thomasen P. Gene expression in the human endolymphatic sac: the solute carrier molecules in endolymphatic fluid homeostasis. Otol Neurotol. 2015 Jun;36(5):915-22.
53. Moller MN, Kirkeby S, Vikesa J, Nielsen FC, Caye-Thomasen P. Expression of histamine receptors in the human endolymphatic sac: the molecular rationale for betahistine use in Menieres disease. Eur Arch Otorhinolaryngol. 2016 Jul;273(7):1705-10.
54. Hu BH, Zhang C, Frye MD. Immune cells and non-immune cells with immune function in mammalian cochleae. Hear Res. 2018 May;362:14-24.
55. O’Malley JT, Nadol JB Jr, McKenna MJ. Anti CD163+, Iba1+, and CD68+ cells in the adult human inner ear: normal distribution of an unappreciated class of macrophages/microglia and implications for inflammatory otopathology in humans. Otol Neurotol. 2016 Jan;37(1):99-108.
57. Kampfe Nordstrom C, Danckwardt-Lilliestrom N, Laurell G, Liu W, Rask-Andersen H. The human endolymphatic sac and inner ear immunity: macrophage interaction and molecular expression. Front Immunol. 2019 Feb;9:3181.
58. Moller MN, Kirkeby S, Vikesa J, Nielsen FC, Caye-Thomasen P. Gene expression demonstrates an immunological capacity of the human endolymphatic sac. Laryngoscope. 2015 Aug;125(8):E269-75.
59. Broderick L. Hereditary autoinflammatory disorders: recognition and treatment. Immunol Allergy Clin North Am. 2019 Feb;39(1):13-29.
60. Martinez-Quiles N, Goldbach-Mansky R. Updates on autoinflammatory diseases. Curr Opin Immunol. 2018 Dec;55:97-105.
61. Adams JC, Seed B, Lu N, Landry A, Xavier RJ. Selective activation of nuclear factor kappa B in the cochlea by sensory and inflammatory stress. Neuroscience. 2009 May;160(2):530-9.
62. Nie H, Zheng Y, Li R, Guo TB, He D, Fang L, et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat Med. 2013 Mar;19(3):322-8.
63. Ren J, Li H, Lu Y. The determinations of tumor necrosis factor and interleukin 6 in serum of patients with sudden sensorineural hearing loss. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 1998 Jul;12(7):311-3.
64. Rahman MU, Poe DS, Choi HK. Etanercept therapy for immunemediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol. 2001 Sep;22(5):619-24.
65. Keithley EM, Wang X, Barkdull GC. Tumor necrosis factor alpha can induce recruitment of inflammatory cells to the cochlea. Otol Neurotol. 2008 Sep;29(6):854-9.
66. Wang X, Truong T, Billings PB, Harris JP, Keithley EM. Blockage of immune-mediated inner ear damage by etanercept. Otol Neurotol. 2003 Jan;24(1):52-7.
67. Lobo D, Trinidad A, Garcia-Berrocal JR, Verdaguer JM, Ramirez-Camacho R. TNFalpha blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis. Eur Arch Otorhinolaryngol. 2006 Jul;263(7):622-6.
68. Kassner SS, Schottler S, Bonaterra GA, Stern-Strater J, Sommer U, Hormann K, et al. Proinflammatory and proadhesive activation of lymphocytes and macrophages in sudden sensorineural hearing loss. Audiol Neurootol. 2011;16(4):254-62.
69. Suslu N, Yilmaz T, Gursel B. Utility of immunologic parameters in the evaluation of Meniere’s disease. Acta Otolaryngol. 2009 Nov;129(11):1160-5.
70. Svrakic M, Pathak S, Goldofsky E, Hoffman R, Chandrasekhar SS, Sperling N, et al. Diagnostic and prognostic utility of measuring tumor necrosis factor in the peripheral circulation of patients with immune-mediated sensorineural hearing loss. Arch Otolaryngol Head Neck Surg. 2012 Nov;138(11):1052-8.
72. Blesa S, Cortijo J, Mata M, Serrano A, Closa D, Santangelo F, et al. Oral N-acetylcysteine attenuates the rat pulmonary inflammatory response to antigen. Eur Respir J. 2003 Mar;21(3):394-400.
73. Angeli SI, Abi-Hachem RN, Vivero RJ, Telischi FT, Machado JJ. LN-Acetylcysteine treatment is associated with improved hearing outcome in sudden idiopathic sensorineural hearing loss. Acta Otolaryngol. 2012 Apr;132(4):369-76.
74. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr;356(6372):768-74.
76. Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: implications for inflammatory processes. Proc Natl Acad Sci U S A. 2004;101(26):9745-50.
77. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010 Feb;10(2):89-102.
79. Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol. 2010 Mar;6(3):158-66.
80. Arend WP. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum. 2001 Apr;30(5 Suppl 2):1-6.
83. Gosselin D, Rivest S. Role of IL-1 and TNF in the brain: twenty years of progress on a Dr. Jekyll/Mr. Hyde duality of the innate immune system. Brain Behav Immun. 2007 Mar;21(3):281-9.
84. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med. 2003 Jun;348(25):2583-4.
85. Hull KM, Shoham N, Chae JJ, Aksentijevich I, Kastner DL. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol. 2003 Jan;15(1):61-9.
86. Pathak S, Goldofsky E, Vivas EX, Bonagura VR, Vambutas A. IL-1β is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. J Immunol. 2011 Feb;186(3):1870-9.
88. Gattorno M, Martini A. Beyond the NLRP3 inflammasome: autoinflammatory diseases reach adolescence. Arthritis Rheum. 2013 May;65(5):1137-47.
89. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004 Mar;20(3):319-25.
90. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol. 2005 Sep;17(5):586-99.
91. Gattorno M, Tassi S, Carta S, Delfino L, Ferlito F, Pelagatti MA, et al. Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 2007 Sep;56(9):3138-48.
92. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008 Jan;4(1):34-42.
93. Hashimoto S, Billings P, Harris JP, Firestein GS, Keithley EM. Innate immunity contributes to cochlear adaptive immune responses. Audiol Neurootol. 2005 Jan-Feb;10(1):35-43.
95. Mirault T, Launay D, Cuisset L, Hachulla E, Lambert M, Queyrel V, et al. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum. 2006 May;54(5):1697-700.
96. Mantovani A, Bonecchi R, Martinez FO, Galliera E, Perrier P, Allavena P, et al. Tuning of innate immunity and polarized responses by decoy receptors. Int Arch Allergy Immunol. 2003 Oct;132(2):109-15.
102. Elkon R, Milon B, Morrison L, Shah M, Vijayakumar S, Racherla M, et al. RFX transcription factors are essential for hearing in mice. Nat Commun. 2015 Oct;6:8549.
103. Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021 Mar;33(3):127-48.
106. Baxter FO, Came PJ, Abell K, Kedjouar B, Huth M, Rajewsky K, et al. IKKbeta/2 induces TWEAK and apoptosis in mammary epithelial cells. Development. 2006 Sep;133(17):3485-94.
107. Park JS, Kwok SK, Lim MA, Oh HJ, Kim EK, Jhun JY, et al. TWEAK promotes osteoclastogenesis in rheumatoid arthritis. Am J Pathol. 2013 Sep;183(3):857-67.
109. Serafini B, Magliozzi R, Rosicarelli B, Reynolds R, Zheng TS, Aloisi F. Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury. J Neuropathol Exp Neurol. 2008 Dec;67(12):1137-48.
111. Sun SC. Non-canonical NF-κB signaling pathway. Cell Res. 2011 Jan;21(1):71-85.
113. Gilmore TD, Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene. 2006 Oct;25(51):6887-99.
114. Ren Z, Wang L, Cui J, Huoc Z, Xue J, Cui H, et al. Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities. Pharmazie. 2013 Aug;68(8):689-94.
117. Tansey MG, Szymkowski DE. The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov Today. 2009 Dec;14(23-24):1082-8.
118. Lis K, Kuzawinska O, Balkowiec-Iskra E. Tumor necrosis factor inhibitors: state of knowledge. Arch Med Sci. 2014 Dec;10(6):1175-85.
119. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 Mar;73(3):492-509.
121. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2010 Apr;6(4):232-41.
122. Ren K, Torres R. Role of interleukin-1beta during pain and inflammation. Brain Res Rev. 2009 Apr;60(1):57-64.